Helix Biopharma Corp. Stock
Your prediction
Pros and Cons of Helix Biopharma Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Helix Biopharma Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Helix Biopharma Corp. | - | - | - | - | - | - | - |
| Resverlogix Corp | 6.300% | 3.846% | 21.622% | 101.493% | 150.000% | -35.714% | -87.838% |
| Enwave Corporation | -4.460% | -6.140% | -15.079% | 65.891% | 55.072% | -33.229% | -73.871% |
| Aurinia Pharmaceuticals Inc. | 0.700% | 0.708% | 0.746% | 45.937% | 54.626% | 203.551% | 12.918% |
News
BioCardia Narrows Loss in Fiscal Q2
BioCardia (NASDAQ:BCDA), a clinical-stage cell therapy company focused on treatments for heart disease, released its financial results for the second quarter of 2025 on August 11, 2025. The company
Helix Energy Q2 Revenue Falls 17%
Helix Energy Solutions Group (NYSE:HLX), a diversified offshore energy services provider, reported weaker-than-expected Q2 2025 results, released on July 23, 2025. The headline was a disappointing